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1. Introduction 
Issues of early detection of colorectal cancer with reference to the value of screening 
programmes and the role of the primary care practitioner 
Colorectal cancer (CRC) is the most common newly-diagnosed cancer, one of the leading 
causes of illness and death in the Western world, and the second most common cause of 
cancer morbidity in Europe. Yet, CRC is a preventable disease and, if detected early, highly 
treatable. Early detection and prevention are health care strategies of critical importance for 
the reduction of CRC morbidity and mortality. In a number of countries, screening 
programmes have been implemented on nationwide scale since the 1960s for other forms of 
cancer. The early detection of cancer increases the likelihood of successful outcomes, but in 
order to have early detection, education and training promoting early diagnosis and 
resulting in increased screening, participation is needed. Additionally, the effectiveness of 
screening can be measured by the reduction on mortality, but it greatly depends upon 
tangible and sometimes intangible factors, contingent on setting and target population; it is 
essential, for example, to identify and screen the appropriate target population and to 
overcome implementation and uptake barriers. All of these issues, with emphasis on 
obstacles encountered at the level of general and family practice are highlighted in a recent 
editorial in Family Practice (Lionis and Petelos, 2011).  
Although the screening is performed in the context of public health, and for the benefit of 
the community, the rights and welfare of the individual should also be respected. The role 
of the General Practitioner/Family Practitioner (GP/FP) and generally of the Primary Care 
Provider (PCP) is challenging yet instrumental in achieving this balance, as it is at that level 
screening is initiated (Viguier et al, 2011). The involvement and the role of GPs and PCPs in 
convincing patients to participate and initiate CRC screening should be further explored and 
elucidated, as it is of key importance in cultural and organisational context and health policy 
issues (Sarfaty, 2006). CRC screening of asymptomatic population groups is currently 
recommended in the USA and many European countries, and a number of pilot and 
nationwide programmes have been developed for this purpose. More specifically, mass 
screening programmes are currently established in 13 of 39 European countries (Pox et al, 
2007; Manfredi et al, 2011) with feasibility studies undertaken as pilot actions in many more. 
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Although many of these screening programmes, both opportunistic and population-based 
are already implemented, and screening and early detection of adenomatous polyps has 
been shown to be effective in the reduction of CRC morbidity and mortality, the rate of 
screening participation remains low in many population groups at risk for the disease. Good 
news have recently arrived from across the Atlantic, where decision analysis tools were 
employed to inform recommendation updates and “microsimulation modelling 
demonstrated that declines in CRC death rates are consistent with a relatively large 
contribution from screening” (Edwards et al, 2010), nevertheless, similar efforts are lacking 
in some European countries, an issue that is given its due importance in this chapter. The 
success in the US can be attributed to the efforts of international organisations and national 
task forces, as they have resulted in a level of high awareness of CRC screening among US 
primary care providers (PCPs) in the US (Klabunde et al, 2003; Levin et al, 2008), but also in 
certain European countries. However, there is a variation in the evidence that explains the 
low rate of CRC screening, especially in younger patients (Walsh et al, 2009), while, few 
physicians recommend screening for the majority of their patients (McGregor et al, 2004). 
Compounding this effect is evidence that close to a quarter of physicians report not 
following national screening guidelines, and only half reported the adoption of 
recommendations that was consistent with the guidelines (Meissner at al, 2006), another key 
issue that requires special attention. 
Additionally, very few PCPs use chart reminders or outreach programmes to contact patient 
populations most likely to benefit from screening (Klabunde et al, 2009). There is limited 
research focusing on obstacles and barriers, and the role of the physician-patient 
relationship plays in determining participation in screening programmes, especially when it 
comes to ethnic and culturally diverse groups (Lionis and Petelos, 2011). The importance of 
culturally relevant strategies for designing and implementing screening programmes has 
been already highlighted (Tu et al, 2006). Additionally, the role of socioeconomic disparities 
in CRC screening has been highlighted and documented (Meissner et al, 2011) if not 
explored in detail (Aubin-Auger et al, 2011), thus indicating a need for a close collaboration 
between medical and social care scientists in order to improve the requisite understanding 
for increased compliance to CRC screening recommendations. To compound the increasing 
complexity of national guidelines and the sensitivity of implementing them to culturally and 
linguistically varied patients, support through interventions focusing on organizational 
changes and further education and training for PCPs on early diagnosis, prevention and 
health promotion is needed. These are all issues that this chapter attempts to address. All of 
these factors are relevant for and have an impact on the ongoing debate about the role of 
GPs/FPs and PCPs, as well as the contribution these have on the effective implementation 
of screening programmes, opportunistic and population-based. 
From all of the above one can surmise that the early detection of CRC is an issue of 
complexity requiring clear messages to increase the awareness and performance of the 
health care actors. This is another objective of the present chapter. Thus, the particular aims 
of this chapter are: (a) to provide information about the recommendations issued by certain 
large national and international organizations, including those issued by the U.S. Preventive 
Services Task Force (US PSTF) on the use of the available screening tests for the early 
detection of CRC and adenomas for average-risk subjects, (b) to critically review the role of 
clinical physicians and mainly PCPs in the early detection of CRC, (c) to explore issues with 
an impact on CRC screening, and, finally, (d) to highlight some quality issues relevant to 
CRC screening and relevant guidelines for quality assurance mechanisms in the relevant 
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processes. The chapter starts with concepts and definitions, proceeds with the 
recommended screening tests and concludes by outlining main points of interest and 
corresponding recommended tasks and actions for PCPs, for the purpose of increasing 
uptake and facilitating implementation of CRC screening programmes. 
2. Concepts and definitions  
Population screening is the systematic application of a suitable test with the aim of 
identifying individuals at a risk of a specific condition or disorder, but who have not sought 
medical attention on account of symptoms for that particular condition or disorder, and 
who can benefit from further investigation or direct preventive action (Wald, 1994). The 
notion differs from opportunistic screening, and it is a systematic process that includes 
certain steps from call or recall to screening, feedback of the results and follow-up in well-
defined intervals. For population screening, the organised framework in which it takes place 
provides opportunities for more effective management, quality assurance and evaluation.  
In our empirical view, understanding of the notion of screening, population or 
opportunistic, greatly varies between health care practitioners with the result of adversely 
impacting the effective implementation of the early detection programmes for CRC. It is for 
this reason we have decided to provide an extensive review on the existing literature and 
consensus criteria to define screening, focusing on CRC screening.  
As stated by Wilson and Jungner in their seminal paper (Wilson and Jungner, 1968) “the 
central idea of early disease detection and treatment is essentially simple. However, the path to its 
successful achievement (on the one hand bringing to treatment those with previously undetected 
disease, and, on the other, avoiding harm to those persons not in need of treatment) is far from simple 
though sometimes it may appear deceptively easy”. On the basis of whether early detection is 
possible at an early stage of the disease and taking into consideration whether an 
appropriate treatment is available, they attempted to formulate criteria that could help 
guide the selection of conditions and population groups suitable for screening. They also 
noted case-finding differences, depending on whether it is performed by a public health 
agency or by a general practitioner, and, almost four decades ago, emphasised the aspect of 
cost by underlining the importance of assessing effectiveness not only from an individual, 
but also from a public health perspective.  
The fast pace of genetic research and the advent of new therapies has resulted in the 
generation of many other lists of screening criteria; most of them based to a greater or lesser 
degree on the Wilson-Jungner criteria. Additionally, even when consensus at the national or 
regional level is reached on which set of criteria to apply, there are other social, ethical and 
even logistical considerations to be examined. More recent trends on patient-centric and 
evidence-based health care, as well as cost-effectiveness and quality assurance, have 
resulted through a series of consultations to the modified Wilson and Jungner criteria 
(Andermann et al, 2008). In these amended criteria, opportunistic screening, essentially case-
finding performed outside a framework of an organised programme as the one required to 
ensure such criteria are met, is, therefore, not a valid alternative; additionally to being less 
efficient it is also more costly, and, most importantly, quality assurance mechanisms cannot 
be embedded in a standardised fashion in such a process.  
The definition of an “organised” screening programme according to the International 
Agency for Research on Cancer (IARC) includes: 1) an explicit policy with specified age 
categories, method and interval for screening; 2) a defined target population; 3) a 
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management team responsible for implementation; 4) a health-care team for decisions and 
care; 5) a quality assurance structure; and 6) a method for identifying cancer occurrence and 
death in the population (IARC 2005). Such organised population-based screening 
programmes have a predefined specific population, according to epidemiological data and 
on the basis of target age and geographical area, and during all the stages, from the 
invitation of the eligible individuals to the assessment procedures following testing, a 
specific protocol is followed. As mentioned, quality aspects of the process can be better 
addressed, as for example during follow-up (Miles et al, 2004). Furthermore, such screening 
programmes usually do not incur any costs for the participants.  
It is important to have also a concrete idea regarding more abstract terms determining the 
usefulness and, even, the effectiveness of screening tests, and to keep such definitions in 
mind. Although these terms have been widely used, there is also great variation of their 
understanding and usage in clinical decision-making. For example, the ability of a measure 
or test to predict a subsequent event is a form of validity. On the basis of such a criterion we 
determine the predictive value of a test. The positive predictive value (PPV) in terms of 
detection through FOBT screening is defined as “the percentage of people with detection of at 
least one lesion/adenoma/advanced adenoma/cancer at follow-up colorectal screening among those 
with positive tests who have attended follow-up colorectal screening” [Adapted from the European 
guidelines for quality assurance in colorectal cancer screening and diagnosis. 2011. 
European Commission, Directorate General for Health and Consumers, EAHC — Executive 
Agency for Health and Consumers, World Health Organisation], whereas a positive test is, 
effectively, an abnormal result leading to further investigation (i.e. colonoscopy) or the 
removal of a lesion, for example, according to the protocol of the organized screening 
programme. By alluding to a false-positive result, we effectively mean that although the test 
indicated disease is present this is not the case. In a true-positive test, the result is correct 
and the disease is really present. Similarly a false-negative test indicates a disease-free 
subject has been tested, but the disease is present and might remain undetected if there is no 
further testing, symptoms, etc., whereas a true-negative test indicates a disease-free subject 
has been tested. Prevalence of the disease affects not only the positive predictive value of a 
screening test but also its negative predictive value, i.e. the probability that the person 
subjected to the screening test is truly free from the disease when a negative (normal) test 
result is obtained.  
Two concepts often discussed in relation to true- and false- positive and negative results are 
sensitivity and specificity and both terms have an important impact on the PCP decisions on 
which of the available tests for the early detection of CRC should be recommended. The 
sensitivity refers to the number of cases the test can identify or in more simple words the 
probability of one diagnostic test telling the truth when the disease exists. It gives us a 
certainty that true positives will not be missed. Specificity refers to the accuracy of the 
finding or in simple words the probability in telling the truth when the disease is absent. 
Ideally, a test should be both highly sensitive and specific. To that direction, the US 
Preventive Services Task Force and the Institute of Medicine (IoM) recommend the fecal 
occult blood test (FOBT) test, and more specifically the guaiac test (gFOBT) for screening 
programmes. Nevertheless, when used on its own, it has relatively low sensitivity, whereas 
the a combination with a more sensitive test, such as the fecal immunochemical test (FIT) 
could help to render screening programmes more effective (Allison, et al, 2007). Another 
interesting consideration, especially given the public health context of mass screening, is 
cost-effectiveness and how it correlates to specificity and sensitivity. Although uncertainty 
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remains, the assessment of a screening program based on FIT for a one-year period in 
France seemed to be the most cost-effective approach (Hassan, et al, 2011). More research is 
necessary, as for example indicating what the best cut-off levels for colonoscopy referral are, 
without compromising sensitivity, to determine optimal public health approaches. 
3. Screening tests, guidelines for CRC and the importance of early detection  
As previously mentioned, CRC can be curable when diagnosed at an early stage. Also, CRC 
mostly develops from colorectal non-malignant precursor lesions, thus, rendering it a 
preventable disease through the removal of premalignant lesions. Systematic early detection 
and removal at the “adenoma-phase” can prevent the occurrence of CRC and markedly 
decrease overall population incidence (Winawer et al, 1993), as human colon carcinogenesis 
progresses to the carcinoma pathway via the dysplasia-adenoma phase. 
The readers of this chapter are aware from previous chapters of this book that there are 
various tumour staging systems, the ones mainly used in Europe being Duke’s classification 
and TNM (Tumour, Node, Metastasis) classification of malignant tumours, introduced by 
the Union Internationale Contra le Cancer (UICC) and the American Joint Committee on 
Cancer (AJCC). Despite the fact TNM yields greater information, there are several major 
issues due to the reclassification of the system. Most importantly, there seems to be great 
disparity between the therapeutic decision-making and the TNM staging, with multiple 
TNM staging versions being used in different countries and great variance in reporting. It 
has been argued that changes should only occur after extensive discussion within the 
scientific community (Quirke et al, 2010), and it is essential to note that the reporting on a 
nationwide scale for any given CRC screening programme should be performed on the basis 
of the same staging system. Lesion reporting within the frame of the screening programme 
should be standardized to allow for better evaluation and reporting, and, consequently, 
improved outcomes. TNM stages and version, frequency of CRC and distribution of TNM 
stages should be reported along with the presence of non-neoplastic lesions. According to 
the report of the EU on CRC quality guidelines (European Commission, Directorate General 
for Health and Consumers, EAHC — Executive Agency for Health and Consumers, World 
Health Organisation, 2011), without explicit criteria for the diagnosis and staging of early 
adenocarcinoma unnecessary radical resection would result in severe overtreatment, raising 
the morbidity and mortality in the context of the programmes.  
Various screening technologies are currently available, from the more established Guaiac 
faecal occult blood tests (gFOBT) and immunochemical FOBT to sigmoidoscopy and 
colonoscopy, as well as combinations (i.e. combined FOBT with sigmoidoscopy) to the new 
screening technologies, as CT colonography, stool DNA and capsule endoscopy. Early 
reports during the previous decade suggested that biennial screening by FOBT reduces CRC 
mortality, as for example in the French (Faivre et al, 2004) and Danish populations 
(Jørgensen et al, 2002). This fact lead WHO (World Health Organization) and OMED (World 
Organization for Digestive Endoscopy) to suggest a choice of FOBT that should take into 
account dietary compliance to recommendations, but also colonoscopy resources (Young et 
al, 2002). Prior to any recommendation for screening tests for CRC, the PCPs should be able 
to recognise whether the individual visiting the practice/office is at average, increased or at 
high risk for CRC. In other words, to be able to identify whether the particular individual 
truly belongs to the target population of the screening programme or –should there not be 
one available– whether there is reason for referral in the context of opportunistic screening.  
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In Australia, the Department of Health and Aging has issued clinical practice guidelines for 
the prevention, early detection and management, and national population-based screening 
programs are in place for various cancers, from breast cervix and to bowel (CRC) 
(Australian DoHA, 2011). Also, the National Bowel Cancer Screening Program Register 
plays an important role in the programme, as it assists participants through the screening 
pathway, allows for reminders and follow-ups without taxing local resources and GPs. 
There are online tools and decision-aids available to GPs and information in twenty 
languages targeted at patients. Pre-invitation, invitation, follow-up letters, FOBT kit 
instructions and an information booklet are all provided in all of these languages and are 
also available online. Additionally, a qualitative evaluation of opinions, attitudes and 
behaviours influencing CRC were examined in the pilot phase of the national screening 
programme and the report was published and integrated in future planning [A Qualitative 
Evaluation of Opinions, Attitudes and Behaviours Influencing the Bowel Cancer Screening 
Pilot Program: Final Report August 2005]. Most interestingly, the invitation is sent directly 
to the candidate participant and it is not necessary to nominate a physician in the forms 
submitted, although participants are encouraged to nominate a doctor in the context of 
follow-up if the FOBT is positive: 
a. If no doctor is nominated, the FOBT results will only be sent to the participant. 
b. If a doctor is nominated, the results of the FOBT will be sent to the participant and their 
doctor.  
c. If the FOBT result is positive it is explained that it will be necessary to discuss the result 
with a doctor.  
The American Cancer Society (ACS) and the National Colorectal Cancer (NCC) in 
cooperation with the Thomas Jefferson University have edited a Primary Care Clinician’s 
Evidence-Based Toolbox and Guide (Sarfaty, 2008). According to this guide, an individual is 
at an average risk when s/he has no first-degree relatives with a history of either CRC or 
adenomatous polyps and no illness or past health problems have been reported (Sarfaty, 
2008). For individuals at average risk, GPs are recommended to initially take a medical 
history, including age, symptoms, family medical history, and also individual history with a 
focus on bowel diseases and dietary habits, and to perform a clinical examination including 
a digital rectal examination. Also, various CRC screening guidelines and recommendations 
have been issued, both by national and international organisations and institutions. In 2008, 
a joint effort of the ACS and the American Gastroenterology Association was released 
regarding certain modalities including stool tests, flexible sigmoidoscopy (FS), colonoscopy 
(CS), double-contrast barium enema (DCBE), computer tomography, colonography (CTC) 
(McFarland, et al 2008). Those joint guidelines also stressed the importance of prevention of 
CRC important tasks for PCPs. The US Preventive Services Task Force (US PSTF) 
recommends routine asymptomatic screening for three cancer sites, including that of breast, 
CRC and cervix, mainly because they are asymptomatic to a high degree in early staging, 
have a high 5-year survival rate when the cancer is localised, and as there is a strong 
evidence on the screening effectiveness (Cardarelli, 2010).  
In terms of a recommended start and stop age for screening, the ACS has issued guidelines 
for the early detection of CRC and polyps with recommended screening beginning at age 50 
for both men and women (ACS, 2011). The US PSTF recommends a screening for average-
risk men and women 50 years of age and older, with colonoscopy every 10 years, flexible 
sigmoidoscopy or DCBE every five years and faecal occult blood test every year (U.S. 
Preventive Services Task Force, 2011). In a supporting document, this Task Force 
www.intechopen.com
 
Early Detection of Colorectal Cancer and Population Screening Tests 
 
51 
summarises its recommendations and recommends screening for CRC using an FOBT, 
sigmoidoscopy, or colonoscopy in adults beginning at the age of 50 years and continuing 
until the age of 75 (Grade: A Recommendation). However, US PSTF recommends against 
screening for CRC in adults over 85 (Grade: D Recommendation), while it concludes that the 
evidence is insufficient to assess the benefits of CT colonography and faecal DNA testing for 
CRC as screening modalities. Judging the benefits against harms, the American Task Force 
discusses among the benefits of the less invasive CRS screening the number of colonoscopies 
that may be reduced. However, it recommends that for any positive test there is a follow-up 
with colonoscopy. The Task Force Recommendation statement underlines that the benefits 
of CRC detection and early intervention decline at the age of 75 years, thus it leaves the 
decision for a routine screening at individual level. There is, as described, a lot of 
information, but slightly conflicting evidence and advice. Nevertheless, participation of the 
50-75 years age group increased by 13.1% reaching 65.4%, whereas a significant CRC 
incidence decline was noted in 35 states and mortality declined in 49 states and DC (CDC, 
2011). Further efforts are currently being made in the field of patient engagement and 
patient-reported outcomes, and in the context of comparative effectiveness research (PCORI, 
2011). 
In the United Kingdom, Cancer Research UK underlines the importance of screening for the 
reduction of CRC mortality and has elaborated upon the role of FOBT and flexible 
sigmoidoscopy (Cancer Research UK, 2011). This institute refers to evidence provided by 
four RCTs where the use of FOBT every two years reduced CRC mortality by 15% to 18% in 
people aged 45-74 years. Centralised systems, such as the Australian and, to a certain extent, 
the UK system, remove pressure from the individual GP and the organisational capacity at 
practice level, but could potentially result in a loss of involvement and a lowered feeling of 
responsibility.  
An individual is at increased risk when s/he has a personal and family history of CRC or 
adenomatous polyps but without reporting any of the high-risk familiar syndromes. Those 
hereditary syndromes include: the hereditary non-polyposis CRC (HNPCC), the familiar 
adenomatous polyposis (FPP) and the attenuated PAP (APAP). In this group, the clinical 
physicians and the PCP should change their strategy from screening to regular surveillance, 
and the tests that primarily detect cancer should be replaced by more sensitive diagnostic 
approaches and particularly colonoscopy, which should start at age 40 or younger (Sarfaty, 
2008). The National Institute for Health and Clinical Excellence (UK) has recently published 
a new guideline on colonoscopic surveillance for the prevention of people with ulcerative 
colitis, Crohn’s disease or adenomas (NICE, 2011). At the third category where the 
probability of developing CRC is high, the PCPs should be more cautious when 
recommending screening and surveillance. A family history of an adenomatous polypus or 
CRC in a relative under the age of 50 is suggesting a high probability of the presence of any 
of the above high-risk hereditary syndromes and the clinical physician requires genetic 
testing; a close collaboration with hospital specialists at a centre with expertise should be 
established (Sarfaty, 2008).  
In Europe, the high degree of heterogeneity in health care systems, policy, roles, screening 
programme resources and very different values in local and regional settings had previously 
created a rather fragmented picture. There are ongoing efforts toward harmonisation, for 
example, recently developed guidelines (2011) in an effort under the auspices of the 
European Commission, focus on quality assurance and provide clear and concise 
information to facilitate decision-making at the GP/FP and PCP levels. As illustrated by 
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Table 1, an evidenced-based brief overview of various conventional screening methods is 
given, although new technologies resulting in more modern forms of screening are not 
assessed for lack of evidence; some information regarding cost-effectiveness is provided 
along with the recommendations and examined in more details in the report (European 
Commission, Directorate General for Health and Consumers, EAHC — Executive Agency 
for Health and Consumers, World Health Organisation, 2011) 
Finally, it is important to underline that early detection is directly dependent on acceptance 
of the screening test by both provider and patient, as well as the uptake of the screening 
programme. For example, early versions of stool DNA (sDNA) testing lacked the requisite 
sensitivity and markers, but improved sDNA tests are now available. It is important to 
understand patient preferences regarding screening options for selecting the right tool for a 
given population; for example, whether a non-invasive test is preferred to colonoscopy or 
whether accuracy is considered much more important than discomfort. In a study by Schroy 
et al, (2002), those preferring colonoscopy to sDNA or FOBT rated accuracy as the most 
important factor, whereas those rating concerns about discomfort or frequency of testing as 
the most important parameter preferred sDNA. Most subjects preferred a shared (54%) or 
patient-dominant (34%) decision-making process.  
As previously highlighted, removal of all adenomas, without accurately distinguishing 
between those which will become malignant and those which will not, will effectively result 
in excessive overtreatment, and it is for this reason that newer screening tests, such as the 
sDNA, focusing on genomic changes affecting associated biological and metabolic processes 
should not be overlooked as options necessitating further research -particularly because of 
their potential to avoid iatrogenic care, but also because they might better reflect patient 
preferences for certain population groups (Sillars-Hardebol, et al, 2012).  
 
[Adapted from the European guidelines for quality assurance in colorectal cancer 
screening and diagnosis. 2011. European Commission, Directorate General for Health and 
Consumers, EAHC — Executive Agency for Health and Consumers, World Health 
Organisation.] 
Guaiac FOBT 
There is good evidence that invitation to screening with FOBT using the guaiac test 
reduces mortality from colorectal cancer (CRC) by approximately 15% in average risk 
populations of appropriate age 
RCTs have only investigated annual and biennial screening with guaiac FOBT (gFOBT) 
(II). To ensure effectiveness of gFOBT screening, the screening interval in a national 
screening programme should not exceed two years 
Circumstantial evidence suggests that mortality reduction from gFOBT is similar in 
different age ranges between 45 and 80 years. The age range for a national screening 
programme should at least include 60 to 64 years in which CRC incidence and mortality 
are high and life expectancy is still considerable. From there the age range could be 
expanded to include younger and older individuals, taking into account the balance 
between risk and benefit and the available resources 
Immunochemical FOBT 
There is reasonable evidence from an RCT that iFOBT screening reduces rectal cancer 
mortality, and from case control studies that it reduces overall CRC mortality; Additional 
www.intechopen.com
 
Early Detection of Colorectal Cancer and Population Screening Tests 
 
53 
evidence indicates that iFOBT is superior to gFOBT with respect to detection rate and 
positive predictive value for adenomas and cancer 
Given the lack of additional evidence, the interval for iFOBT screening can best be set at 
that of gFOBT, and should not exceed three years 
In the absence of additional evidence, the age range for a screening programme with 
iFOBT can be based on the limited evidence for the optimal age range in gFOBT trials 
Sigmoidoscopy 
There is reasonable evidence from one large RCT that flexible sigmoidoscopy (FS) 
screening reduces CRC incidence and mortality if performed in an organised screening 
programme with careful monitoring of the quality and systematic evaluation of the 
outcomes, adverse effects and costs 
The available evidence suggests that the optimal interval for FS screening should not be 
less than 10 years and may even be extended to 20 years 
There is limited evidence suggesting that the best age range for FS screening should be 
between 55 and 64 years. After age 74, average-risk FS screening should be discontinued, 
given the increasing co-morbidity in this age range 
Colonoscopy 
Limited evidence exists on the efficacy of colonoscopy screening in reducing CRC 
incidence and mortality. However, recent studies suggest that colonoscopy screening 
might not be as effective in the right colon as in other segments of the colorectum 
Limited available evidence suggests that the optimal interval for colonoscopy screening 
should not be less than 10 years and may even extend up to 20 years 
Indirect evidence suggests that the prevalence of neoplastic lesions in the population 
below 50 years of age is too low to justify colonoscopic screening, while in the elderly 
population (75 years and above) lack of benefit could be a major issue. The optimal age for 
a single colonoscopy appears to be around 55 years. Average risk colonoscopy screening 
should not be performed before age 50 and should be discontinued after age 74 
Combination of FOBT and sigmoidoscopy 
The impact on CRC incidence and mortality of combining sigmoidoscopy screening with 
annual or biennial FOBT has not yet been evaluated in trials. There is currently no 
evidence for extra benefit from adding a once-only FOBT to sigmoidoscopy screening 
New screening technologies under evaluation 
There currently is no evidence on the effect new screening tests under evaluation on CRC 
incidence and mortality. New screening technologies such as CT colonography, stool DNA 
testing and capsule endoscopy should therefore not be used for screening the average-risk 
population 
Cost-effectiveness 
Costs per life-year gained for both FOBT and endoscopy screening strategies are well 
below the commonly-used threshold of US$ 50 000 per life-year gained (LYG) 
There is some evidence that iFOBT is a cost-effective alternative to gFOBT 
Available studies differ with respect to what screening strategies are most cost-effective. 
No recommendation of one screening strategy over the others can be made based on the 
available evidence of cost-effectiveness 
Table 1. Recommendations and conclusions  
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Finally, the concepts of colonoscopic surveillance and screening for recurrent CRC should 
receive attention by PCPs. The adenomatous precursors of CRC are present in over 30% of 
individuals over 55 (Eide, 1991), placing them at higher risk of developing CRC, but the 
removal of these lesions reduces risk to that of the general population (Citarda et al, 2001). 
Recurrent CRC, as for example following resection, also necessitates an intensive 
surveillance programme, as the detection at an asymptomatic stage can result in survival 
benefit (Renehan, et al, 2002). This means that surveillance and follow-up programmes 
should also be combined or evaluated along with a screening programme.  
4. Primary care and CRC: Tasks and steps for screening implementation in 
primary care  
One of the most important factors for the effective implementation of a CRC screening 
programme is the involvement of a PCP, particularly of the GP or the FP, in convincing 
targeted individuals to participate and to initiate the screening. The PCPs have multiple and 
varying tasks, more specifically to (Sarfaty, 2008): 
1. Assess the risk of developing CRC and increase the risk awareness, as described 
above. 
2. Discuss options with patients/individuals and effectively engage in shared decision-
making (SDM) – this would ensure patient perspectives and preferences are consistent 
to decisions made. 
3. Convince to participate – this task requires communication and consultation skills, as 
well as an established continuity of care. 
4. Implement the initial tests: those primarily used to detect cancer, including the annual 
Guaiac-based occult blood test (gFOBT), the annual faecal immunochemical test (FIT), 
or stool DNA test (sDNA). 
5. Consider and assess the available screening resources and capacity: it is an important 
task for PCPs, who should be aware of the available resources in their district or health 
region capacity, as well as patient limitations (e.g. socioeconomic, mobility, etc.), to 
determine the optimal referral pathway for the test(s) that detect adenomatous polyps 
and CRC (FS, CS, DCBE, CRC).  
6. To make the necessary arrangement to complete the CRC screening. 
One of the most challenging issues that the PCPs encounter is to convince the average risk 
individual to use a simple and inexpensive test to initially detect if any hidden blood is 
present in stools, constituting a strong indication of the presence of an adenomatous polyp 
or CRC. To achieve it, an effective doctor-patient communication should be established, and 
the purpose of the GPs/PCPs might also need to be re-assessed by further education or 
training on early diagnosis, prevention and promotion. The role of a multidisciplinary team 
is also essential. FOB Testing serves this role, although it has received criticism because of 
the lack of specificity, particularly when the test is dehydrated, and because of the 
subsequent increase of the associated costs of screening programmes (WHO, Rudy and 
Zdon, 2000). FIT, also, fulfils this purpose; it is a simple procedure: the stool sample is 
collected by the individual/patient at home, and the completed test is sent to a laboratory or 
to the PCPs office. Usually two samples from different bowel movements are required and 
the instructions on sampling procedures on how the water sample should be transferred by 
the brush onto the test card are clear and readily understood. 
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Another important task for PCPs and other practitioners is to educate their patients/clients 
to contact the PHC services when some warning signs are experienced and among them are 
(Rudy and Zdon, 2000): 
- Hematochezia 
- Melaena 
- Anaemia resulting from occult blood loss 
- Change in bowel habits 
Prior to the decision of the PCP to refer the subjects to either CS/FT or CT should be 
explored the access to that screening method and consider the existing diagnostic capacity 
resources (Sarfaty and Wender, 2007).  
Finally, another essential consideration in the PCP decision to implement screening tests 
for early detection of CRC is that of quality of life. Quality of life in evidence-based 
medicine should always reflect the preferences of patients, as patient-centeredness is its 
cornerstone. Despite the fact everyone values particular aspects of life differently, all 
aspects of life that may be affected adversely or in a beneficial manner by aspects of health 
and illness should be taken into consideration. For screening programmes, it is important 
to understand the cultural context in which it is performed or is to be performed and to 
ensure the values of the patients are taken into consideration when determining and/or 
assessing outcomes. 
5. Obstacles to implementing CRC screening in primary care 
Obstacles in primary care 
As mentioned above, the CRC screening rate increase does not seem to apply in many 
countries and regions and the associated obstacles and barriers that have already been 
reported in the literature (Lionis and Petelos, 2011) could be classified as follows: 
 Obstacles at doctor level: Obstacles reported by the GPs were relevant to the difficulties 
in being convinced especially when signs and symptoms were lacking. There was, in 
other words, confusion in addressing difficulties stemming from conflict between 
personal experiences and public health implications (Aubin-Auger et al, 2011). Also, 
there is research indicating that even in countries with established screening 
programmes only 50% of the GPs considered themselves to be sufficiently trained, as 
for example in France (Viguier et al, 2011). 
 Obstacles at patient level: Researchers examined obstacles at patient level and how 
these were linked to the physician-patient interaction and communication. For example, 
cancer screening did not fall in with the perception of some patients regarding health 
care, and they failed to identify benefits outside the context of familiar high-risk groups. 
Potentially inadvertently reflecting specificity and sensitivity issues, participants were 
afraid of poor technical skills, and taking ownership of the risk for performing the test, 
resulting in false positive or false negative results (Aubin-Auger et al. 2011). Mirroring 
the high number of GPs who do not feel they are sufficiently trained, patients cited the 
absence of recommendation as one of the most important reasons for not undergoing 
screening (Viguier et al, 2011).  
 Obstacles at doctor-patient level: GPs and patients agreed the lack of symptoms and 
lack of familial risk were two of the main reasons for doubting how useful such a test 
could be, the GPs thought that the patients misunderstood the process and were 
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afraid of reactions to false negative results, whereas the patients complained about 
time, as well as the constipation effect from repeating the test, and did not express 
fears about such results (Aubin-Auger et al, 2011). Further evidence (Schroy et al, 
2011) indicates that screening intentions and test ordering are adversely affected 
when patient and provider preferences differ. Interestingly, compounding previously 
reported data (Serra et al, 2008), having a screening habit (e.g. mammography) 
proved to be a positive factor for women, whereas increased participation was 
reported for those with a higher educational level, particularly for male patients. 
Without diminishing the importance of facilitators, a patient having a relative having 
already performed gFOBT was more likely to accept the test, but friends and family 
were not identified as obstacles.  
Further barriers: 
Cultural and linguistic barriers were also touched upon by these researchers, but not 
explored in detail; it is highlighted that even the wording a doctor uses has an effect and 
that further research is necessary (Lionis and Petelos, 2011). There is evidence that by 
employing culturally and linguistically relevant approaches for FOBT promotion, screening 
participation increases in target populations of low-income and/or less acculturated 
minority patients (Tu et al, 2006). Indeed, a challenge of equal significance to guideline 
adherence and compliance in screening is ensuring equity of access to screening. Part of 
ensuring equity of access is to ensure awareness issues have been addressed for all ethnic 
and culturally diverse groups. A study of all the patients aged 50-60 registered in general 
practices for a UK region (West Midlands), with a total number of over eleven thousand 
respondents, examined factors that contributed positively or negatively on behaviour 
toward screening (Taskila et al, 2009). People without a screening habit (men), older people, 
and those with Indian ethnic backgrounds were more likely to have negative attitudes, 
whereas Black-Caribbean ethnic background people reporting abdominal pain, bleeding or 
tiredness were more likely to have a positive attitude. This great variation in attitudes 
indicates that there are different needs to be addressed for increasing awareness and 
highlight the importance of culturally relevant strategies for designing and implementing 
screening programmes (Taskila et al, 2009). Evidence amasses from various countries, with a 
study focusing specifically on FOBT use, along with the subsequent investigation of a 
positive result (Bampton et al, 2005). Researchers established that both indications for use 
and follow-up of a positive result varied according to the ethnicity of the GP and 
independently of the medical training received (Koo et al, 2011). Additionally, it was 
indicated that the ethnicity of the patient and, similarly to results of other research, 
associated linguistic and cultural barriers affect screening uptake and was noted that this 
may adversely affect the health of immigrant populations. 
To address all the obstacles and barriers previously mentioned, it is necessary to embrace 
the perspective of the users of screening programmes, and also to examine screening 
under the prism of public health perspective. A recently conducted review highlights the 
need for policy supporting both screening delivery and organisational transformation in a 
manner that promotes improvement of operational features for preventive services 
(Senore et al, 2010). The researchers examined recently proposed conceptual frameworks 
that were aimed at identifying key elements and, thus, potential targets for interventions 
aiming to improve screening (Cole et al, 2009 and Federici et al, 2005). The models 
developed conceptualised these potential targets at various levels: the organizational 
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context in which health care delivery and provision are taking place, the practice itself, 
and the structural and operational characteristics of given settings, and also examined the 
provider and patient levels. The researchers concluded that although a given intervention 
may be implemented at one or multiple levels, the factors determining uptake and 
participation are, indeed, correlated with all of these levels in an interconnected and 
interdependent manner. 
In concluding this section, the role of the PCPs is extremely complex, and although research 
on obstacles, barriers and limitations is starting to create a more robust evidence base, 
further qualitative and translational research is required to identify best practices and 
intervention transferability. Additionally, policy measures for the purpose of supporting 
screening delivery mechanisms are required, and, similarly, policy should aim to facilitate 
the organisational changes necessary for creating and supporting the operational features of 
preventive services. 
6. Increasing the CRC screening rate 
Although messages about the effectiveness of CRC screening have been widely available, 
there are still concerns in terms of both physician involvement and PC user participation in 
CRC screening. This is not a message that concerns CRC screening per se, but prevention 
and health promotion activities undertaken by GPs in Europe. There are significant gaps 
between GP knowledge and practice in Europe, already reported upon (Brotons et al, 2005). 
Evidence from the literature indicates that less than one third of the PC physicians use chart 
reminders and 15% use outreach mechanisms to contact patients needing screening 
(Klabunde et al, 2009). Investment has been made on efforts and research programs to assess 
the impact of quality improvement intervention programs. One of them combined diverse 
components, such as performance activities, delivery system design, electronic medical 
record tools and patient activation (Ornstein et al, 2010), and reported promising results in 
the Evidence-Based Toolbox and Guide we currently have (Sarfaty, 2008). Thus, the 
implementation of educational programmes for PCPs and patients in addition to the 
development of shared-decision making tools, given the differing perspectives between 
doctor and patient, seem imperative, as otherwise lack of consensus could adversely impact 
the CRC screening rate (Schroy et al, 2011). 
A page invitation to the health practitioners to avoid certain errors has been made and 
among them the following: 
- To screen for CRC with only a digital rectal exam or with a single sample from a stool 
blood test 
- Recommend screening with colonoscopy at average risk more often than every 10 
years or CT colonography, DBCE or flexible sigmoidoscopy more often than five 
years 
A toolkit for a systematic approach in tracking and increasing screening for public health 
improvement of CRC intervention was prepared for the Agency for Health Care Research 
and Quality (AHRQ). It delivers tools, process guidelines, tips and evidence of the 
intervention effectiveness (Harris et al, 2010). It is strongly recommended for PCPs, health 
care planners and managers. However, the role of PCPs in increasing the CRC screening 
rate remains a key component. According to the ACS and NCS, the positive impact of its 
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advice is well documented, and the magnitude of the doctor’s impact is considerable 
(Sarfaty, 2008). 
7. Designing a national CRC screening programme/framework 
We have seen the importance and potential of CRC screening in detail. The importance of 
screening taking place in an organised framework for optimal results, as for example in 
nationwide programmes, has also been examined and noted. As many European countries 
are still in the process of designing such a programme and many other countries globally 
are far from implementing such interventions, it is important to see how to best learn from 
other experiences and how to use lessons already learned to help us morph a flexible and 
robust model that can be adapted according to regional and local needs to ensure high 
acceptance, uptake and, indeed, equal access and reduced disparities. Thus, we decided to 
include in this section some key issues that health planners, health policy makers and public 
health decision makers should take into account when considering the design and 
implementation of a CRC screening programme. 
Many of the countries in which a nationwide programme is implemented have extensively 
reported on the outcomes and evaluation of such programmes. Australia has introduced 
such a programme, but reporting indicated the needs and beliefs of minority groups, as for 
example indigenous Australians, were not always taken into consideration, with stronger 
drives, as for example economic benefit at country level, determining the approach 
undertaken and the strategy selected (Christou and Thompson, 2010).  
To start, the need of conducting a feasibility study should be evaluated. According to Bowen 
et al, (2009) performing a feasibility study may be indicated when “(a) community 
partnerships need to be established, increased, or sustained, (b) there are few previously published 
studies or existing data using a specific intervention technique, (c) prior studies of a specific 
intervention technique in a specific population were not guided by in-depth research or knowledge of 
the population’s socio-cultural health beliefs, by members of diverse research teams, or by researchers 
familiar with the target population and in partnership with the targeted communities, (d) the 
population or intervention target has been shown empirically to need unique consideration of the 
topic, method, or outcome in other research or (e) previous interventions that employed a similar 
method have not been successful, but improved versions may be successful; or previous interventions 
had positive outcomes but in different settings than the one of interest”. By quickly reviewing 
these grounds it becomes apparent CRC programmes, independently of whether they are 
still being designed or already implemented, are prime candidates for qualitative research 
via feasibility studies. These pilot actions can help elicit patient preferences and elucidate 
obstacles adversely affecting participation. In terms of results, even small modifications to 
existing programmes or design can greatly affect outcomes. For example, a sound review 
being the starting point for deploying such a pilot action, recent systematic reviews of 
interventions in Australia, indicated that organisational level changes were the most 
effective in terms of screening behaviour enhancement. It is important to note necessary 
modifications for increased effectiveness were those that included non-physicians in the 
screening process (Christie et al, 2008, Wardle et al, 2003, Vernon 1997). Language and 
literacy barriers are, of course, the most difficult to overcome, as illustrated by the Alaskan 
and Australian Aboriginal examples, and can only be adequately researched and addressed 
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through engagement of local actors and community leaders, strong community orientation 
and high level of awareness of the PHPs, including most importantly nursing and all other 
available healthcare personnel –especially in rural or remote areas. 
Additionally, elements of the care pathway ought to be assessed in context and real settings, 
and, especially where pragmatic trials are impossible, difficult or unethical. Participation in 
and completion of the screening test is not the only necessary part to ensure successful 
outcomes, as there has to be a follow up with the appropriate diagnostic testing. (Christou 
and Thompson, 2010).  
Screening utilisation is also influenced by behavioural factors and health economics 
parameters, as well as by the organizational and cultural settings (Senore et al, 2010). A 
theoretical framework to explain the adoption of health-related behaviours is needed to 
underpin any given implementation effort. Models conceptualizing elements of the health 
care provision have been proposed, providing targets for intervention at patient and 
provider levels (Stone et al, 2002; Bastani et al, 2004, Senore et al, 2010). However, it is 
important to note that although any given intervention component may act upon more than 
one levels, screening uptake is interdependent on all these factors (Senore et al, 2010). 
Consideration of multidisciplinary teams is also essential. These teams can help direct 
resources along a predefined, according to the evidence-base, care pathway ensuring 
effective, efficient and sustainable implementation and, thus, better results. As we have 
previously discussed, CRC screening is complex and comprises of different stages involving 
the participation of different health care actors. For example, all abnormal results should be 
followed-up and after-care service following treatment should be available. Nevertheless, 
only a small portion of health plans monitor follow-up care (Klabunde et al, 2003). 
Multidisciplinary participation can help implement interventions that have added value at 
patient, provider and even public health-health care system level. For example same day 
follow-up for abnormal FS, offering on-site colonoscopy seems to lead to better compliance 
(Stern et al, 2000; Senore et al, 2010). Another benefit in the involvement of nursing and 
clerical staff is the integration of quality indicators and quality assurance mechanisms in 
delivery processes and their monitoring as part of standardised care delivery without 
draining on valuable resources.  
8. CRC screening: An issue of quality assurance in modern health care 
systems 
Quality issues in colorectal cancer screening have been previously discussed in editorials in 
the journals of Quality in Primary Care and Family Practice (Lionis, 2007, Lionis and Petelos, 
2011). These editorials address issues relevant to improvement of uptake of CRC screening 
with the use of cognitive methods and the translation of the Health Belief Model into 
education and training programs for health care providers. The authors call for a closer 
collaboration between medical and social care scientists, and reveals another important 
challenge that PCPs face: addressing health inequalities in a changing and financially 
restrained world, where for example, minority groups showcase low adoption rates of 
preventive measures and screening tests.  
As previously mentioned, the Directorate General for Health and Consumers, with tasks 
funded by the EU Health programme (CRC screening grant No 2005317), led an effort 
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aiming to develop EU guidelines on best practice in CRC screening, which resulted in the 
publication of the first edition of the European guidelines for quality assurance in colorectal 
cancer screening and diagnosis in February of 2011 (European Commission, Directorate 
General for Health and Consumers, EAHC — Executive Agency for Health and Consumers, 
World Health Organisation). The guidelines systematically examine the evidence for 
efficacy and effectiveness of CRC screening and outline the guiding principles for 
organising CRC screening programmes. Most importantly, the authors underline the 
importance of the availability of comprehensive, evidence-based quality assurance 
guidelines that address all the steps of a screening programme, including invitation, 
information, surveillance and any other subsequent care, as a key factor to the success of 
any cancer screening programme. Finally, the authors advocate the widespread application 
of standardised indicators, as recommended and elaborated upon in the guidelines, to 
facilitate quality management and promote information exchange in the context of 
continuous quality improvement. 
9. Epilogue 
This chapter serves as an overview of the guidance available for CRC screening in the US, 
UK, Europe and Australia and briefly discussed the important role of GPs/FPs and PCPs, in 
general, in increasing the CRC screening rate. Although the literature is rich in information, 
guidelines and recommendation for CRC screening, there is room for improvement. It is to 
important invest in translating primary research into practice and combine qualitative and 
quantitative evidence for relevant, contextualised training and educational interventions, 
both at patient and provider levels. 
10. References and internet resources 
10.1 References 
Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz 
AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV. (2007). Screening for 
colorectal neoplasms with new fecal occult blood tests: update on performance 
characteristics. J Natl Cancer Inst. Vol. 3;99(19):1462-70. Epub 2007, Sep 25. 
Andermann, A., Blancquaert, I., Beauchamp, S., Déry, V.. (2008). Revisiting Wilson and 
Jungner in the genomic age: a review of screening criteria over the past 40 years. 
Bull World Health Organ. Vol. 86(4):317-9. 
Aubin-Auger, I., Mercier, A., Lebeau. J.P., Baumann, L., Peremans, L., Van Royen, P. (2011). 
Obstacles to colorectal screening in general practice: a qualitative study of GPs and 
patients. Family Practice. Advance Access: cmr020 first published online May 6, 
2011 doi:10.1093/fampra/cmr020.  
Bampton, P.A., Sandford, J.J., Cole, S.R., Smith, A., Morcom, J., Cadd, B., Young, G.P. (2005). 
Interval faecal occult blood testing in a colonoscopy based screening programme 
detects additional pathology. Gut. Vol. 54(6):803-6. 
Bastani, R., Yabroff, K.R., Myers, R.E. and Glenn, B. (2004). Interventions to improve follow-
up of abnormal findings in cancer screening. Cancer. Vol. 101:1188–1200. 
www.intechopen.com
 
Early Detection of Colorectal Cancer and Population Screening Tests 
 
61 
Bowen D.J., Kreuter M., Spring B., Cofta-Woerpel L., Linnan L., Weiner D., Bakken S., (...), 
Fernandez M. (2009) How We Design Feasibility Studies. American Journal of 
Preventive Medicine. Vol. 36(5):452-457.  
Brotons, C., Björkelund, C., Bulc, M., Ciurana, R., Godycki-Cwirko, M., Jurgova, E., Kloppe, 
P., Lionis, C., Mierzecki, A., Piñeiro, R., Pullerits, L., Sammut, M.R., Sheehan, M., 
Tataradze, R., Thireos, E.A., Vuchak, J.; EUROPREV network. (2005) Prevention 
and health promotion in clinical practice: the views of general practitioners in 
Europe. Prev Med. Vol. 40(5):595-601. 
Cardarelli, R. (2010). The Role of Primary Care Providers in Cancer Screening. Primary Care 
Institute. (Accessed online November 10, 2011:  
 http://www.centerforcommunityhealth.org/Portals/14/Reports/PCPCancerBrief
Final%282%29.pdf). 
Christie, J., Itzkowitz, S., Lihau-Nkanza, I., Castillo, A., Redd, W., Jandorf, L. (2008). A 
randomized controlled trial using patient navigation to increase colonoscopy 
screening among low-income minorities. Journal of the National Medical Association. 
Vol. 100(3):278-284.  
Christou, A., and Thompson, S.C. (2010). “How could the National Bowel Cancer Screening 
Program for Aboriginal people in Western Australia be improved?” Report to the 
WA Bowel Cancer Screening Implementation Committee, Department of Health, 
Western Australia and Combined Universities Centre for Rural Health.  
Citarda, F., Tomaselli, G., Capocaccia, R., Barcherini, S., Crespi, M. (2001). The Italian 
Multicentre Study Group: Efficacy in standard clinical practice of colonoscopic 
polypectomy in reducing colorectal cancer incidence. GUT. Vol. 48:812–815 
Cole, S.R., Young G.P., Byrne, D., Guy, J.R., and Morcom, J. (2002). Participation in screening 
for colorectal cancer based on a faecal occult blood test is improved by 
endorsement by the primary care practitioner. J Med Screen. Vol (9):147–152. 
Edwards, B.K., Ward, E., Kohler, B.A., Eheman, C., Zauber, A.G., Anderson, R.N., Jemal, 
A., Schymura, M.J., Lansdorp-Vogelaar, I., Seeff, L.C., van Ballegooijen, M., 
Goede, S.L., Ries, L.A. (2010). Annual report to the nation on the status of cancer, 
1975-2006, featuring colorectal cancer trends and impact of interventions (risk 
factors, screening, and treatment) to reduce future rates. Cancer. Vol. 1;116(3):544-
73. 
Eide, T.J. (1991). Natural history of adenomas. World J Surgery. Vol. 15:3–6. 
European Commission, Directorate General for Health and Consumers, EAHC — Executive 
Agency for Health and Consumers, World Health Organisation. (2011). European 
guidelines for quality assurance in colorectal cancer screening and diagnosis. 
(Accessed online September 10, 2011:  
 http://bookshop.europa.eu/is-bin/INTERSHOP.enfinity/WFS/EU-Bookshop-
Site/en_GB/-/EUR/ViewPublication-Start?PublicationKey=ND3210390). 
Faivre, J., Dancourt, V., Lejeune, C., Tazi, M.A., Lamour, J., Gerard, D., Dassonville, F., 
Bonithon-Kopp, C. (2004). Reduction in colorectal cancer mortality by fecal occult 
blood screening in a French controlled study. Gastroenterology. Vol. 126(7):1674-
80. 
www.intechopen.com
 
Colorectal Cancer – From Prevention to Patient Care 
 
62
Federici A, Giorgi Rossi P, Bartolozzi F, Farchi S, Borgia P & Guasticchi G. (2005). Survey on 
colorectal cancer screening knowledge, attitudes, and practices of general practice 
physicians in Lazio, Italy. Prev Med. Vol(41):30–35. 
Harris, D.M., Borsky, A.E., Stello, B. et al. (2010). Toolkit for the System Approach to Tracking 
and Increasing Screening for Public Health Improvement of Colorectal Cancer 
Intervention. AHRQ Publication No 11-0016. 
Hassan, C., Benamouzig, R., Spada, C., Ponchon, T., Zullo, A., Saurin, J.C., Costamagna, G. 
(2011). Cost effectiveness and projected national impact of colorectal cancer 
screening in France. Endoscopy. Vol. 43(9):780-93. Epub 2011 May 27. 
IARC (2005). Cervix Cancer Screening. IARC Handbooks of Cancer Prevention. Volume 10. 
Jørgensen, O.D., Kronborg, O., Fenger, C. (2002). A randomised study of screening for 
colorectal cancer using faecal occult blood testing: results after 13 years and seven 
biennial screening rounds. Gut. Vol. 50(1):29-32. 
Klabunde, C.N., Frame, P.S., Meadow, A., Jones, E., Nadel, M., Vernon, S.W. (2003). A 
national survey of primary care physicians' colorectal cancer screening 
recommendations and practices. Prev Med. Vol. 36(3):352-62. 
Klabunde, C.N., Lanier, D., Nadel M.R, et al. (2009). Colorectal Cancer Screening by primary 
care physicians: recommendations and practices; 2006-2007. Am J Prev Med. 
Vol.(37):8-16.  
Koo J.H., You B., Liu K., Athureliya M.D., Tang C.W., Redmond D.M., Connor S.J., Leong R. 
(2011). Colorectal cancer screening practices is influenced by ethnicity of medical 
practitioner and patient. J Gastroenterol Hepatol. doi: 10.1111/j.1440-
1746.2011.06872.x. [Epub ahead of print] 
Levin, B., Lieberman, D.A., McFarland, et al. (2008). Screening and surveillance for the 
early detection of colorectal cancer and adenomatous polyps, 2008: a joint 
guideline from the American Cancer Society, the US Multi-Society Task Force on 
Colorectal Cancer, and the American College of Radiology. CA Cancer J. Clin. Vol 
58:130-160.  
Lionis C, and Petelos E. (2011). Early detection of colorectal cancer: barriers to screening in 
the primary care setting. Family Practice. Vol 28(6):589-91. 
Lionis, C. (2007). Colorectal cancer screening and the challenging role of general 
practitioner/family physician: an issue of quality. Quality in Primary Care. Vol. 
15:129-131.  
McFarland, E.G., Levin, B., Lieberman, D.A., Pickhart, P., Johnson, C.D., Glick, S.N., Brooks, 
D., Smith, R.A. (2008). Revised colorectal screening guidelines: Joint effort of the 
American Cancer Society. CA Cancer J Clin Vol 2008;58:160.  
McGregor, S.E., Hilsden, R.J., Murray, A., Bryant, H.E. (2004) Colorectal cancer screening: 
practices and opinions of primary care physicians. Prev Med. Vol 39(2):279-85. 
Meissner, H.I., Breen, N., Klabunde, C.N., Vernon, S.W. (2006). Patterns of colorectal cancer 
screening uptake among men and women in the United States. Cancer Epidemiol 
Biomarkers Prev. Vol 15(2):389-94. 
Miles, A., Cockburn, J., Smith, R.A., Wardle J. (2004). A perspective from countries using 
organized screening programs. Cancer. Vol. 101(5):201-1213.  
www.intechopen.com
 
Early Detection of Colorectal Cancer and Population Screening Tests 
 
63 
Ornstein, M., Nemeth, L.S., Jenkins, P.G., Nietert, P.J. (2010). Colorectal cancer 
screening in Primary Care: Translating Research into Practice. Medical Care Vol 
48: 900-906. 
Pox, C., Schmiegel, W., Classen, M. (2007). Current status of screening colonoscopy in 
Europe and in the United States. Endoscopy 39:168–173. 
Quirke, P., Cuvelier, C., Ensari, A., Glimelius, B., Laurberg, S., Ortiz, H., Piard, F., Punt, C.J., 
Glenthoj, A., Pennickx, F., Seymour, M., Valentini, V., Williams, G., Nagtegaal, J.D. 
(2010). Evidence-based medicine: the time has come to set standards for staging, 
Journal of Pathology. Vol. 221(4):357-360. 
Renehan AG, Egger M, Saunders MP, O'Dwyer ST. (2002). Impact on survival of intensive 
follow up after curative resection for colorectal cancer: systematic review and meta-
analysis of randomised trials. BMJ. Vol. 6;324(7341):813. 
Rudy, D.R., Zdon, M.J. (2000). Update on Colorectal Cancer. Am Fam Physician Vol 61:1759-
70,1773-4.  
Sarfaty, M. (2006) How to Increase Colorectal Cancer Screening Rates in Practice: a Primary 
Care Clinician’s Evidence-Based Toolbox and Guide. Atlanta, GA: The American 
Cancer Society, National Colorectal Cancer Roundtable and Thomas Jefferson 
University. (Accessed online November 10, 2011:  
 http://www.cancer.org/acs/groups/content/documents/document/acspc-
024588.pdf).  
Sarfaty, M., Wender, R. (2007). How to increase colorectal cancer screening rates in practice. 
CA Cancer J Clin. Vol. 57(6):354-66. 
Schroy, P.C. 3rd, Lal, S., Glick, J.T., Robinson, P.A., Zamor, P., Heeren, T.C. (2007). Patient 
preferences for colorectal cancer screening: how does stool DNA testing fare? Am J 
Manag Care. Vol. 13(7):393-400.  
Schroy, P.C., Mylvaganam, S., Davidson, P. (2011). Provider perspectives on the utility of a 
colorectal cancer screening decision aid for facilitating shared decision-making. 
Health Expect September 8 [Epub ahead of print], doi:10.1111/j.1369-
7625.2011.00730.x. 
Senore, C., Malila, N., Minozzi, S., Armaroli, P. (2010). How to enhance physician and public 
acceptance and utilisation of colon cancer screening recommendations. Best Pract 
Res Clin Gastroenterol. Vol 24(4):509-20. 
Sillars-Hardebol, A.H., Carvalho, B., van Engeland, M., Fijneman, R.J., Meijer, G.A. (2012). 
The adenoma hunt in colorectal cancer screening: defining the target. Journal of 
Pathology. Jan;226(1):1-6. doi: 10.1002/path.3012. Epub 2011 Nov.  
Stern, M.A., Fendrick, A.M., McDonnell, W.M., Gunaratnam, N., Moseley, R., Chey, W.D. A 
randomized, controlled trial to assess a novel colorectal cancer screening strategy: 
the conversion strategy–a comparison of sequential sigmoidoscopy 
andcolonoscopy with immediate conversion from sigmoidoscopy to colonoscopy in 
patients with an abnormal screening sigmoidoscopy. Am J Gastroenterol. Vol. 
95:2074–2079.  
Stone, E.G., Morton, S.C., Hulscher, M.E., Maglione, M.A., Roth, E.A., Grimshaw, J.M., 
Mittman, B.S., Rubenstein, L.V., Rubenstein, L.Z., Shekelle, P.G. (2002). 
www.intechopen.com
 
Colorectal Cancer – From Prevention to Patient Care 
 
64
Interventions that increase use of adult immunization and cancer screening 
services: a meta-analysis. Ann Intern Med. Vol. 136:641–651. 
Sung, J.J., Lau, J.Y., Goh, K.L., Leung, W.K.; Asia Pacific Working Group on Colorectal 
Cancer. (2005) Increasing incidence of colorectal cancer in Asia: implications for 
screening. Lancet Oncol. Vol 6(11):871-6. 
Taskila T., Wilson S., Damery S., Roalfe A., Redman V., Ismail T., Hobbs R. (2009). Factors 
affecting attitudes toward colorectal cancer screening in the primary care 
population. Br J Cancer. Vol 21;101(2):250. 
Tu S.P., Taylor V., Yasui Y, Chun A., Yip M.P., Acorda E. et al. (2006). Promoting culturally 
appropriate colorectal cancer screening through a health educator: a randomized 
controlled trial. Cancer. Vol 107:959–966. 
Vernon SW. (2003). A national survey of primary care physicians' colorectal cancer 
screening recommendations and practices. Prev Med. Vol. 36(3):352-62. 
Viguier J, Calazel-Benque A, Eisinger F, Pivot X. (2011). Organized colorectal cancer 
screening programmes: how to optimize efficiency among general practitioners. 
Eur J Cancer Prev. Vol. 20 Suppl 1:S26-32. 
Wald N.J. (1994). Guidance on terminology. J Med Screen. 1: 76. 
Walsh, J.M., Posner, S.F., Perez-Stable, E.J. (2002) Colon cancer screening in the ambulatory 
setting. Prev Med. Vol 35(3):209-18. 
Wardle, J., Williamson, S., McCaffery, K. (2003). Increasing attendance at colorectal cancer 
screening: testing the efficacy of a mailed, psychoeducational intervention in a 
community sample of older adults. Health Psychology. Vol. 22:99-105.  
Wilson, J.M.G., and Jungner, G. (1968). Principles and practice of screening for  disease. 
Geneva: World Health Organization.(Accessed online October 25, 2011 from:  
 http://www.who.int/bulletin/volumes/86/4/07-050112BP.pdf).  
Winawer, S.J., Zauber, A.G., Ho, M.N., O'Brien, M.J., Gottlieb, L.S., Sternberg, S.S., Waye, 
J.D., Schapiro, M., Bond, J.H., and Panish,J.F. (1993). Prevention of colorectal cancer 
by colonoscopic polypectomy. The National Polyp Study Workgroup, New England 
Journal of Medicine. Vol. 329(27):1977-1981. 
Young, G.P., St John, D.J., Winawer, S.J., Rozen, P. WHO (World Health Organization) & 
OMED (World Organization for Digestive Endoscopy). (2002). Choice of faecal 
occult blood tests for colorectal cancer screening: recommendations based on 
performance characteristics in population studies: a WHO (World Health 
Organization) and OMED (World Organization for Digestive Endoscopy) report. 
Am J Gastroenterol. Vol 97(10):2499-507. 
10.2 Internet resources 
American Cancer Society (ACS) Guidelines for the early detection of cancer: Colorectal 
cancer and polyps.  
 (Accessed online September 19, 2011:  
 http://www.cancer.org/Healthy/FindCancerEarly/CancerScreeningGuidelines/a
merican-cancer-society-guidelines-for-the-early-detection-of-cancer).  
www.intechopen.com
 
Early Detection of Colorectal Cancer and Population Screening Tests 
 
65 
Australian Government Department of Health and Ageing. (2008). Clinical Practice Guidelines 
for the Prevention, Early Detection and Management of Colorectal Cancer – A Guide for 
General Practitioners. (3rd ed.).  
 (Accessed online August 11, 2011:  
  http://www.health.gov.au/internet/screening/publishing.nsf/Content/bw-gp-
crc-guide). 
Australian Government Department of Health and Ageing. (2005) A Qualitative Evaluation of 
Opinions, Attitudes and Behaviours Influencing the Bowel Cancer Screening Pilot 
Program. Final Report. Screening Monograph: 2/2005.  
 (Accessed online September 16, 2011: 
 http://www.health.gov.au/internet/screening/publishing.nsf/Content/qual-
eval-cnt).  
Australian Population Health Development Principal Committee. (2008). Population-Based 
Screening.  
 (Accessed online September 16, 2011:  
 http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content
/other-pop-health#framework).  
Cancer Research UK. Bowel cancer – screening and prevention.  
 (Accessed online September 15, 2011:  
 http://info.cancerresearchuk.org/cancerstats/types/bowel/screeningandpreventi
on/). 
Centers for Diseases Control and Prevention (US) MMWR. Vital Signs: Colorectal Cancer 
Screening, Incidence, and Mortality: United States, 2002—2010. 
 (Accessed online September 15, 2011: 
 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6026a4.htm?s_cid=mm602
6a4_w). 
National Institute for Health and Clinical Excellence, (2011). NICE publishes new guidelines 
on colonoscopic surveillance for the prevention of colorectal cancer in people with 
ulcerative colitis, Crohn’s disease or adenomas.  
 (Accessed online August 9, 2011:  
 http://www.nice.org.uk/newsroom/pressreleases/2011045colonoscopicsurveillan
ce.jsp). 
International Agency for Research on Cancer. Early detection and Prevention - Quality 
Assurance Group Resources. 
 (Accessed online August 11, 2011:  
 http://www.iarc.fr/en/researchs-groups/QAS/current-topics.php). 
Patient-Centered Outcomes Research Institute. (2011-ongoing) Review and Synthesis of 
Evidence for Eliciting the Patient’s Perspective in Patient-Centered Outcomes 
Research. Literature review and interviews.  
 (Accessed online September 19, 2011: 
 http://www.pcori.org/patient-centered-outcomes-research/ and 
 http://www.pcori.org/committee-charters/). 
U.S. Preventive Services Task Force. (2008). Screening for Colorectal Cancer.  
 (Accessed online August 8, 2011: 
www.intechopen.com
 
Colorectal Cancer – From Prevention to Patient Care 
 
66
 http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm). 
World Health Organization. (2011). Screening for Colorectal Cancer.  
 (Accessed online August 1, 2011:  
 http://www.who.int/cancer/detection/colorectalcancer/en/). 
www.intechopen.com
Colorectal Cancer - From Prevention to Patient Care
Edited by Dr. Rajunor Ettarh
ISBN 978-953-51-0028-7
Hard cover, 538 pages
Publisher InTech
Published online 17, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The projections for future growth in the number of new patients with colorectal cancer in most parts of the
world remain unfavorable. When we consider the substantial morbidity and mortality that accompanies the
disease, the acute need for improvements and better solutions in patient care becomes evident. This volume,
organized in five sections, represents a synopsis of the significant efforts from scientists, clinicians and
investigators towards finding improvements in different patient care aspects including nutrition, diagnostic
approaches, treatment strategies with the addition of some novel therapeutic approaches, and prevention. For
scientists involved in investigations that explore fundamental cellular events in colorectal cancer, this volume
provides a framework for translational integration of cell biological and clinical information. Clinicians as well as
other healthcare professionals involved in patient management for colorectal cancer will find this volume
useful.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Christos Lionis and Elena Petelos (2012). Early Detection of Colorectal Cancer and Population Screening
Tests, Colorectal Cancer - From Prevention to Patient Care, Dr. Rajunor Ettarh (Ed.), ISBN: 978-953-51-0028-
7, InTech, Available from: http://www.intechopen.com/books/colorectal-cancer-from-prevention-to-patient-
care/early-detection-of-colorectal-cancer-and-population-screening-tests
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
